Kindred Biosciences to Present at Guggenheim Animal Health Summit
Kindred Biosciences (NASDAQ: KIN) is set to present at the Guggenheim Animal Health Summit on December 7, 2020, at 10am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kindred Biosciences (NASDAQ: KIN) is set to present at the Guggenheim Animal Health Summit on December 7, 2020, at 10am ET. CEO Dr. Richard Chin will join the panel discussing how biologics will transform veterinary practices. Additionally, he will hold one-on-one meetings with investors to discuss recent developments and key therapeutic programs. Kindred Biosciences focuses on developing biologics that improve pets' lives, leveraging validated human medicine targets for safe and effective treatments.
Details
News Market Reaction – KIN
The recorded move for KIN in the trading session of this news was -1.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Dec. 2, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, Chief Executive Officer, will present on the "How Biologics Will Change Veterinary Practices" panel at the Guggenheim Animal Health Summit at 10am ET on Monday, December 7, 2020.
Dr. Chin will also be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, visit: www.kindredbio.com
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-guggenheim-animal-health-summit-301185094.html
SOURCE Kindred Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.